Page 13 - Arix Bioscience News Today

DJ Portfolio Company Disc Medicine Enters Definitive Merger Agreement with Gemini Therapeutics Arix Bioscience PLC (ARIX) Portfolio Company Disc Medicine Enters Definitive Merger Agreement with Gemini

Investegate announcements from Arix Bioscience PLC, Artios initiates Phase 2 study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer

DJ Artios initiates Phase 2 study of Pol? Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer Arix Bioscience PLC (ARIX) Artios initiates Phase 2 study

Arix Bioscience PLC (ARIX) Portfolio Company Disc Medicine Enters Definitive Merger Agreement with Gemini Therapeutics 10-Aug-2022 / 1...

Big company results and important economic data continue to flow steadily on both sides of the Atlantic in the coming week, with potential highlights...

SymBiosis Hires Jahan Ali, PhD as Vice President of Business Development - read this article along with other careers information, tips and advice on BioSpace

DJ Holding(s) in Company Arix Bioscience PLC (ARIX) Holding(s) in Company 22-Jun-2022 / 16:45 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible

Investegate announcements from Arix Bioscience PLC, Result of Annual General Meeting 2022

DJ Result of Annual General Meeting 2022 Arix Bioscience PLC (ARIX) Result of Annual General Meeting 2022 07-Jun-2022 / 16:44 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS

AARHUS, Denmark, May 31, 2022 (GLOBE NEWSWIRE) -- STipe Therapeutics (STipe), a company with a novel approach to leverage the STimulator of INterferon Genes (STING) Pathway, a major driver of